1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–38. https://doi.org/10.1146/annurev-publhealth-031912-114409

2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905–17. https://doi.org/10.1176/appi.ajp.163.11.1905

3. Berman, RM, Cappiello, A, Anand, A, Oren, DA, Heninger, GR, Charney, DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4. https://doi.org/10.1016/S0006-3223(99)00230-9

4. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64. https://doi.org/10.1001/archpsyc.63.8.856

5. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509–23. https://doi.org/10.1146/annurev-med-053013-062946

6. Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2016;81:1–12. https://doi.org/10.1016/j.biopsych.2016.05.005

7. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77. https://doi.org/10.1016/j.neuropharm.2011.07.036

8. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015;40:259–67. https://doi.org/10.1038/npp.2014.261

10. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–95. https://doi.org/10.1038/nature10130

11. Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349–52. https://doi.org/10.1016/j.biopsych.2007.05.028

12. Newport DJ,Div M,Carpenter LL,Mcdonald WM,Potash JB, Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172:950–66. https://doi.org/10.1176/appi.ajp.2015.15040465.

13. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–6. https://doi.org/10.1038/nature17998

14. Yang C, Shirayama Y, Zhang J, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632 https://doi.org/10.1038/tp.2015.136

15. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539–47.

16. Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci. 2005;26:631–8. https://doi.org/10.1016/j.tips.2005.10.005

17. Gass P, Riva MA. CREB neurogenesis and depression. Bioessays. 2007;29:957–61. https://doi.org/10.1002/bies.20658

18. Dwivedi Y, Pandey GN. Adenylyl cyclase-cyclic AMP signaling in mood disorders: role of the crucial phosphorylating enzyme protein kinase A. Neuropsychiatr Dis Treat. 2008;4(1 A):161–76. https://doi.org/10.2147/NDT.S2380

19. Fujita M, Richards EM, Niciu MJ, Ionescu DF, Zoghbi SS, Hong J, et al. cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor HHS public access. Mol Psychiatry. 2017;22:754–9. https://doi.org/10.1038/mp.2016.171

20. Toki S, Donati RJ, Rasenick MM. Treatment of C6 glioma cells and rats with antidepressant drugs increases the detergent extraction of Gα s from plasma membrane. J Neurochem. 1999;73:1114–20. https://doi.org/10.1046/j.1471-4159.1999.0731114.x

21. Donati RJ, Dwivedi Y, Roberts RC, Conley RR, Pandey GN, Rasenick MM. Postmortem brain tissue of depressed suicides reveals increased Gα s localization in lipid raft domains where it is less likely to activate adenylyl cyclase. J Neurosci. 2008;28:3042–50. https://doi.org/10.1523/JNEUROSCI.5713-07.2008

22. Zhang, L, & Rasenick, MM (2010). Chronic treatment with escitalopram but not R-citalopram translocates Gα s from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. J Pharmacol Exp Ther. 2010;332: 977–84. https://doi.org/10.1124/jpet.109.162644.sponse

23. Czysz AH, Schappi JM, Rasenick MM. Lateral diffusion of Gα s in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. Neuropsychopharmacology. 2014;40:1–8. https://doi.org/10.1038/npp.2014.256

24. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci. 2007;8:128–40. https://doi.org/10.1038/nrn2059

25. Wedegaertner PB, Chu DH, Wilson PT, Levis MJ, Bourne HR. Palmitoylation is required for signaling functions and membrane attachment of Gα q and Gα s . J Biol Chem. 1993;268:25001–8.

26. Allen JA, Yu JZ, Dave RH, Bhatnagar A, Roth BL, Rasenick MM. Caveolin-1 and lipid microdomains regulate Gα s trafficking and attenuate Gα s /adenylyl cyclase signaling. Mol Pharmacol. 2009;76:1082–93. https://doi.org/10.1124/mol.109.060160

27. Popp S, Behl B, Joshi JJ, Lanz TA, Spedding M, Schenker E, et al. In search of the mechanisms of ketamine’s antidepressant effects: how robust is the evidence behind the mTor activation hypothesis [version 1; referees: 1 approved, 1 approved with reservations]. F1000Research. 2016;5:634 https://doi.org/10.12688/f1000research.8236.1

28. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 2013;34:287–93.

29. Erb, SJ, Schappi, JM, & Rasenick, MM (2016). Antidepressants accumulate in lipid rafts independent of monoamine transporters to modulate redistribution of the G protein, Gα s . J Biol Chem. 2016;291:19725–33. https://doi.org/10.1074/jbc.M116.727263

30. Tewson PH, Martinka S, Shaner NC, Hughes TE, Quinn AM. New DAG and cAMP sensors optimized for live-cell assays in automated laboratories. J Biomol Screen. 2016;21:298–305. https://doi.org/10.1177/1087057115618608

31. Ulbrich MH, Isacoff EY. Rules of engagement for NMDA receptor subunits. Proc Natl Acad Sci USA. 2008;105:14163–8. https://doi.org/10.1073/pnas.0802075105

32. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry. 1999;46:1181–91. https://doi.org/10.1016/S0006-3223(99)00177-8

33. Browne GJ, Proud CG. Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem. 2002;5368:5360–8. https://doi.org/10.1046/j.1432-1033.2002.03290.x. October

34. Coppell AL, Pei Q, Zetterström TSC. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology. 2003;44:903–10. https://doi.org/10.1016/S0028-3908(03)00077-7

35. Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM. Effects of a ketamine metabolite on synaptic NMDAR function. Nature. 2017;546:E1–E3. https://doi.org/10.1038/nature22084

36. Xue W, Wang W, Gong T, Zhang H, Tao W, Xue L, et al. PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine. Sci Rep. 2016;6:26331 https://doi.org/10.1038/srep26331.

37. Réus GZ, Stringari RB, Ribeiro KF, Ferraro AK, Vitto MF, Cesconetto P, et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res. 2011;221:166–71. https://doi.org/10.1016/j.bbr.2011.02.024

38. Wang Q, Jie W, Liu JH, Yang JM, Gao TM. An astroglial basis of major depressive disorder? An overview. Glia. 2017;65:1227–50. https://doi.org/10.1002/glia.23143

39. Quesseveur G, David DJ, Gaillard MC, Pla P, Wu MV, Nguyen HT, et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry. 2013;3:e253 https://doi.org/10.1038/tp.2013.30.

40. Singh, H, Wray, N, Schappi, JM, & Rasenick, MM (2018). Disruption of lipid-raft localized Gα s /tubulin complexes by antidepressants: a unique feature of HDAC6 inhibitors, SSRI and tricyclic compounds. Neuropsychopharmacology. 2018; 1–11. https://doi.org/10.1038/s41386-018-0016-x

41. Jerabek H, Pabst G, Rappolt M, Stockner T. Membrane-mediated effect on ion channels induced by the anesthetic drug ketamine. J Am Chem Soc. 2010;132:7990–7. https://doi.org/10.1021/ja910843d